Mechanism of Action
A new Target for Diabetes Treatment
The extraordinary solution with the exclusive therapy of Glucox Biotech is that it effectively increase glucose uptake in muscle and dramatically improves insulin sensitivity and thus remove the probable cause of the blunted insulin response.
This is more or less the opposite effect of what drugs on the market do when stimulating insulin secretion from pancreatic cells.
Mechanism of Action
Chronic hyperglycaemia is the main cause of increased oxidative stress in type 2 diabetes patients. The over-production of oxygen free radicals, ROS, and nitric oxide radicals leads to the damage of many cellular compounds including lipids, proteins and nucleic acids.
Glucox Biotech’ lead compound GLX010 is designed to inhibit one of the main enzymes involved in ROS production, thus aiming to reduce ROS production in diabetic subjects.
Based on its scientific excellence and with a strong mission, Glucox Biotech aims to develop and produce the next generation safe and beneficial therapy for future diabetes suffers.
